...
首页> 外文期刊>Journal of biomolecular screening: The official journal of the Society for Biomolecular Screening >Dual-point competition association assay: A fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics
【24h】

Dual-point competition association assay: A fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics

机译:双点竞争缔合分析:一种快速,高通量的动力学筛选方法,用于评估配体-受体结合动力学

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The concept of ligand-receptor binding kinetics is emerging as an important parameter in the early phase of drug discovery. Since the currently used kinetic assays are laborious and low throughput, we developed a method that enables fast and large format screening. It is a so-called dual-point competition association assay, which measures radioligand binding at two different time points in the absence or presence of unlabeled competitors. Specifically, this assay yields the kinetic rate index (KRI), which is a measure for the binding kinetics of the unlabeled ligands screened. As a prototypical drug target, the adenosine A1 receptor (A1R) was chosen for assay validation and optimization. A screen with 35 high-affinity A1R antagonists yielded seven compounds with a KRI value above 1.0, which indicated a relatively slow dissociation from the target. All other compounds had a KRI value below or equal to 1.0, predicting a relatively fast dissociation rate. Several compounds were selected for follow-up kinetic quantifications in classical kinetic assays and were shown to have kinetic rates that corresponded to their KRI values. The dual-point assay and KRI value may have general applicability at other G-protein-coupled receptors, as well as at drug targets from other protein families.
机译:配体-受体结合动力学的概念正在作为药物发现早期的重要参数出现。由于当前使用的动力学测定方法费力且通量低,因此我们开发了一种可进行快速,大幅面筛选的方法。这是一种所谓的双点竞争缔合分析,可在没有标记竞争者存在或存在的情况下,在两个不同的时间点测量放射性配体结合。具体而言,该测定产生了动力学速率指数(KRI),它是所筛选的未标记配体结合动力学的量度。作为原型药物靶标,选择了腺苷A1受体(A1R)进行分析验证和优化。使用35种高亲和力A1R拮抗剂进行的筛选产生了7种KRI值高于1.0的化合物,这表明与目标的解离相对较慢。所有其他化合物的KRI值均小于或等于1.0,这表明其解离速率相对较快。选择了几种化合物用于经典动力学测定中的后续动力学定量,并显示出具有与其KRI值相对应的动力学速率。双点测定和KRI值可能对其他G蛋白偶联受体以及其他蛋白家族的药物靶标具有普遍适用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号